Journal of Neuro-Oncology

, Volume 81, Issue 3, pp 323–325 | Cite as

Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme

  • Giuseppe Luigi Banna
  • Daniela Bettio
  • Marta Scorsetti
  • Pierina Navarria
  • Matteo Simonelli
  • Riccardo Rodriguez Baena
  • Enrico Aimar
  • Paolo Gaetani
  • PierGiuseppe Colombo
  • Felice Rognone
  • Armando Santoro
Letter to the Editor

Abstract

Primary brain high-grade gliomas, excluding glioblastoma are rare and heterogeneous tumors, showing different characteristic mutations and a better prognosis than glioblastomas. The addition of chemotherapy to the radiotherapy in the newly diagnosed disease has not been established yet. We treated 9 patients with newly diagnosed tumors with temozolomide at 75 mg/m2 for 7 days a week during standard radiotherapy, followed by six cycles at 200 mg/m2 on days 1–5 every 28 days. Fluorescence in situ hybridization for the 1 p/19 q loss was performed in seven out of the 9 patients. With a median follow-up of 15 months (range, 8–50), eight patients are alive and one died from disease progression. Four patients had disease progression at 7, 15, 14 and 13 months from the diagnosis. The 1 p/19 q loss was found in 5 patients; three have no evidence of disease, one had partial disease remission and one disease progression. Toxicities included one discitis requiring treatment withdrawal and specific antibiotic therapy, and one transient grade 3 psoriasiform reaction. Based on this small series of patients, the addition of temozolomide to radiotherapy may be recommended.

Keywords

Adjuvant therapy Concomitant therapy High-grade glioma Malignant glioma Radiotherapy Temozolomide 

References

  1. 1.
    Hoffman S, Propp JM, McCarthy BJ (2006) Temporal trends in incidence of primary brain tumors in the United States, 1985–1999. Neuro-oncol 8:27–37PubMedCrossRefGoogle Scholar
  2. 2.
    Sanai N, Alvarez-Buylla A, Berger MS (2005) Neural stem cells and the origin of gliomas. N Engl J Med 353:811–822PubMedCrossRefGoogle Scholar
  3. 3.
    Medical Research Council Brain Tumor Working Party (2001) Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 19:509–518Google Scholar
  4. 4.
    van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715–2722PubMedCrossRefGoogle Scholar
  5. 5.
    Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714PubMedCrossRefGoogle Scholar
  6. 6.
    Levin VA, Hess KR, Choucair A et al (2003) Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 9:981–990PubMedGoogle Scholar
  7. 7.
    Cairncross JG, Ueki K, Zlatescu MC et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479PubMedCrossRefGoogle Scholar
  8. 8.
    See SJ. Gilbert MR (2004) Anaplastic astrocytoma: diagnosis, prognosis, and management. Semin Oncol 31:618–634CrossRefGoogle Scholar
  9. 9.
    Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2006

Authors and Affiliations

  • Giuseppe Luigi Banna
    • 1
    • 7
  • Daniela Bettio
    • 2
  • Marta Scorsetti
    • 3
  • Pierina Navarria
    • 3
  • Matteo Simonelli
    • 1
  • Riccardo Rodriguez Baena
    • 4
  • Enrico Aimar
    • 4
  • Paolo Gaetani
    • 4
  • PierGiuseppe Colombo
    • 5
  • Felice Rognone
    • 6
  • Armando Santoro
    • 1
  1. 1.Department of Medical Oncology and HematologyIstituto Clinico HumanitasMilano, RozzanoItaly
  2. 2.Laboratory of CytogeneticsIstituto Clinico HumanitasMilano, RozzanoItaly
  3. 3.Unit of RadiotherapyIstituto Clinico HumanitasMilano, RozzanoItaly
  4. 4.Unit of Neuro-SurgeryIstituto Clinico HumanitasMilano, RozzanoItaly
  5. 5.Department of PathologyIstituto Clinico HumanitasMilano, RozzanoItaly
  6. 6.Unit of RadiologyIstituto Clinico HumanitasMilano, RozzanoItaly
  7. 7.Unit of Medical OncologyVittorio Emanuele II University HospitalCataniaItaly

Personalised recommendations